To determine the effects of bovine natural surfactant (beractant) instillation on cerebral hemodynamics in preterm infants with respiratory distress syndrome (RDS).
Surfactant replacement therapy for the treatment of respiratory distress syndrome (RDS) has been shown to improve respiratory function and reduce mortality in preterm infants. However, morbidity, particularly intraventricular hemorrhage (IVH), is still of concern. The relationship between surfactant therapy and IVH in preterm infants with RDS has been controversial. Most studies have shown that the incidence of IVH is not reduced significantly after surfactant therapy. 1 However, some investigators in large randomized trials in Europe reported an increased incidence of IVH in surfactant-treated infants. 2 Fluctuations in cerebral blood flow have been implicated in the pathogenesis of IVH, 3 especially in sick preterm infants who reportedly have impaired cerebral blood flow autoregulation. 4, 5 Elimination of fluctuation in cerebral blood flow has been associated with a lower incidence of IVH. 6 In an attempt to relate cerebral blood flow changes to surfactant administration, the influence of surfactant on cerebral blood flow velocity (CBFV) was studied by several investigators but with conflicting results. [7] [8] [9] [10] [11] [12] [13] [14] Most studies involved a small number of patients and used different preparations of surfactant and different techniques of administration.
The purpose of our study was to determine the associated CBFV changes after surfactant administration. We hypothesized that bolus administration of bovine surfactant administration would be associated with significant changes in CBFV.
METHODS
The study protocol was reviewed and approved by The University of Tennessee Institutional Review Board, and informed consent was obtained from a parent. The study was conducted at the newborn intensive care unit of the Regional Medical Center at Memphis. In-
fants were eligible for enrollment in the study if they were Ͻ35 weeks' gestational age without major congenital anomalies, Ͻ48 hours postnatal age, mechanically ventilated, and assessed by the attending physician to require surfactant replacement therapy for RDS. The diagnosis of RDS was based on clinical manifestations and chest radiographic findings of reticulogranular densities, decreased lung volume or hypoaerated lungs, and air bronchograms. Survanta (Abbott Laboratories, Columbus, OH), a natural bovine surfactant (beractant), was administered at a dose of 100 mg of phospholipid per kilogram of birth weight (4 ml/kg) by bolus instillation intratracheally through a 5 French end-hold catheter in four aliquots while briefly disconnecting the endotracheal tube from the ventilator during the bolus instillation. The manufacturer's recommendations for instillation and the changes in head position with each aliquot were followed. FIO 2 was increased to 1.00, and the ventilatory rate was increased to 60 before surfactant instillation. In addition, during the procedure, particular attention was paid to heart rate, to O 2 saturation, and to the presence of surfactant reflux in the endotracheal tube. When a decrease in heart rate to Ͻ100/minute, decrease in O 2 saturation to Ͻ90%, or reflux of surfactant was observed, the proximal inspiratory pressure was increased by increments of 2 to 3 cm H 2 O. We found that a maximum increase from 2 to 4 cm H 2 O might be necessary to manage these side effects. After completion of the procedure, the ventilator settings were slowly returned to baseline settings within the first minute after surfactant. Blood flow velocity waveforms in the pericallosal branch of the anterior cerebral artery were determined by two-dimensional pulsed Doppler ultrasonography with the anterior fontanel serving as an acoustic window. The artery was insonated with a 5-MHz transducer using a pulsed Doppler-imaging system (Toshiba SSH-140A, TochigiKen, Japan) at an angle of insonation of Ͻ10 degrees. Doppler frequencies were recorded when the sharpest visual characteristics were displayed and the best audible signals were heard. Peak systolic, end diastolic, and mean flow velocities in centimeters per second were determined from four consecutive cardiac cycles. CBFV was measured before and at 5, 10, 20, and 30 minutes after the first dose of surfactant instillation. Simultaneously with the Doppler measurements, mean blood pressure (MBP) from an umbilical artery catheter, heart rate, and ventilator settings were recorded. pH, PAO 2 , and PACO 2 before and 30 minutes after surfactant administration were also determined. Data were expressed as the mean Ϯ SD, and the repeated measures analysis of variance was conducted to compare measurements before surfactant and at intervals after surfactant administration with either birth weight strata (Յ1000 gm ϭ 0; Ͼ1000 gm ϭ 1) or gestational age (Յ28 weeks ϭ 0; Ͼ28 weeks ϭ 1) as a factor. A p value Ͻ 0.05 was considered statistically significant. The linear mixed models with random effects were applied to determine any correlation between the serial MBP and mean CBFV (MCBFV) measurements. Next, strata of birth weight and changes in PACO 2 (no change or decrease ϭ 0; increase in measurement after surfactant ϭ 1) were included in the model. Both variables were included because they have been reported to have an effect on CBFV and blood pressure. 4 -6 Furthermore, an increase in PACO 2 has been reported with surfactant administration in various studies, [7] [8] [9] [10] [11] [12] [13] and associated changes in CBFV were explained by PACO 2 changes. 12 The software used for statistical analysis was the S-Plus statistics package (Mathsoft, Seattle, WA).
RESULTS
A total of 30 preterm infants were enrolled in the study with a mean birth weight of 973 Ϯ 338 gm (range: 512 to 1996 gm) and a mean gestational age of 27 Ϯ 2.6 weeks (range: 23 to 33 weeks). A total of 17 infants had a birth weight Յ1000 gm, whereas 13 weighed Ͼ1000 gm. Mean age at surfactant administration was 4.7 Ϯ 2.7 hours. There were no significant changes in pH and PACO 2 before and after surfactant. Before surfactant, the mean pH Ϯ SD and mean PACO 2 Ϯ SD were 7.29 Ϯ 0.07 and 44.4 Ϯ 7.1 torr, respectively. After surfactant therapy, the mean pH was 7.31 Ϯ 0.07; the mean PACO 2 was 42.7 Ϯ 8.3 torr. In 19 babies, PACO 2 values were unchanged or decreased after treatment, whereas PACO 2 increased in 11 infants. PAO 2 increased significantly; mean pre-surfactant PAO 2 was 83 torr, and the 30-minute post-surfactant mean PAO 2 was 130 torr ( p Ͻ 0.05) with no significant change in mean airway pressure.
There were no significant changes in MBP, heart rate, MCBFV, peak systolic flow velocity, and diastolic flow velocity before and after surfactant instillation regardless of gestational age and birth weight (Table 1) . However, individual MCBFV changes were related to MBP changes; MCBFV changed directly with changes in MBP. The expected Figure 1 . Birth weight strata did not have an effect on the relationship between MCBFV and MBP ( p ϭ 0.19), although those infants with a higher birth weight tended to have a higher MCBFV and MBP (Figure 1 ). Thus, from this model, the estimated MCBFV is equal to 5.65 ϩ MBP (0.09 ϫ ⌬PACO 2 ϩ 0.13); p Ͻ 0.001.
DISCUSSION
A transient drop in blood pressure, heart rate, and CBFV has been reported in several studies after porcine natural surfactant (poractant alpha) (Curosurf; Chiesi Farmaceutici, Parma, Italy) instillation. Most of these studies demonstrated significant changes in blood pressure and CBFV within 5 minutes after surfactant administration and then returned to baseline levels within 20 to 30 minutes. [7] [8] [9] [10] [11] In human newborn infants, there are only two studies 12,13 using synthetic surfactant (colfoceril palmitate) (Exosurf; Glaxo Wellcome, Research Triange Park, NC), and these studies showed conflicting results with regard to CBFV changes. There is only one study using bovine natural surfactant that showed no significant changes in CBFV with surfactant administration. 14 In our study, beractant, a bovine natural surfactant, was chosen because it is commonly used for treatment of RDS in the United States; also, data are limited regarding cerebral hemodynamic changes with intratracheal instillation of this surfactant. The dose of surfactant used in our study was the standard dose (100 mg of phospholipids per kilogram (4 ml/kg)) for RDS. Our finding that surfactant administration was not associated with significant changes in MBP, heart rate, and CBFV is comparable with the report of Jorch et al. 14 They showed no significant changes in internal carotid flow velocity and MBP with surfactant administration. Chan et al. 15 also demonstrated no significant changes in MBP and heart rate after a standard dose of beractant instillation. In the animal model, Moen et al. 16 demonstrated that 100 mg/kg beractant instillation in surfactant-depleted newborn piglets caused a decreased vascular resistance, which was compensated for by an increased cardiac output, resulting in a stable MBP. Although a cardiac output measurement was not performed in our study, there were no significant changes in heart rate before and after surfactant. This is indirect evidence indicating no significant change in cardiac output, because the cardiac function of preterm infants has a limited ventricular diastolic compliance, and cardiac output is heart rate-dependent. 17 The influence of dose-dependent porcine surfactant on systemic and cerebral hemodynamics has been demonstrated by a few studies in both animal and human newborn infants 10, 16 by comparing a low dose (100 mg/kg) with a high dose (200 mg/kg). The higher the dose of surfactant, the greater the decrease in MBP and CBFV. To our knowledge, there is no study on human newborns that demonstrates a dose-dependent influence of bovine surfactant on systemic and cerebral circulation.
It is a common practice to increase the peak inspiratory pressure and fraction of inspired oxygen concentration during surfactant instillation to avoid acute drowning effects such as decreases in heart rate, blood pressure, and oxygen saturation. Manipulation of the infant's head and drowning effects during surfactant administration are possible explanations for the decrease in blood pressure and heart rate as demonstrated by Cowan et al. 8 However, in animal studies, no acute systemic hemodynamic changes have been found after normal saline instillation. 16 Rapid instillation of synthetic surfactant has been shown to cause a significantly transient increased CBFV within 5 minutes of administration; however, the finding was related to an increase in carbon dioxide tension. 12 In our study, peak pressure of ventilators was adjusted during surfactant instillation and weaned to the previous setting used before treatment. Also, PACO 2 did not change significantly with surfactant therapy. This may explain the lack of changes in CBFV in our patients. Improvement in oxygenation at 30 minutes after surfactant with the same mean airway pressure of ventilator suggests improved lung compliance and perfusion/ventilation matching. Excessive hyperoxia can cause a decrease in CBFV in human newborn infants but not with as strong an effect as hypocarbia. 18 We adjusted the inspired oxygen concentration immediately after surfactant administration to prevent an excessively high PAO 2 . Because we obtained measurements at 5 minutes after surfactant, it is possible that we missed significant CBFV changes if they occurred. However, studies that have found significant changes in CBFV after surfactant have noted that these changes persist for 10 to 20 minutes posttreatment. 9, [12] [13] [14] Using linear mixed models with random effects, individual changes in MCBFV were related to MBP changes; this finding is consistent with impaired autoregulation of cerebral circulation or a pressure-passive pattern in sick preterm infants as reported by other investigators. 4, 6, 13 Furthermore, we found that associated changes in MCBFV for each unit change in MBP were greater in infants who demonstrated an increase in PACO 2 . These findings suggest that increases in PACO 2 may aggravate cerebral hemodynamic alterations in those with already impaired cerebral autoregulation. Some studies reported that not all preterm infants experienced impaired autoregulation or pressure-passive cerebral circulation. 9, 10 However, it should be noted that these studies involved a small number of infants with a higher birth weight and gestational age than those in our study. Furthermore, surfactant treatment was given prophylactically, which may mean that some infants were included who would not have developed RDS.
Studies on the cerebral hemodynamic effects of surfactant differ according to the preparation of surfactant used (bovine versus porcine natural surfactant), dosage, method of administration (rapid versus slow instillation), and method of measurement (intermittent versus continuous monitoring). However, it is not clear whether these differences can explain the variation in reported results. In animals, the vasodilator effect after porcine surfactant administration can be inhibited by nitric oxide synthase inhibitor. 19 Thus, the mechanism of CBFV and other physiological changes associated with surfactant need further investigation. Our study supports the reported pressure-passive cerebral circulation with a direct relationship between CBFV and blood pressure in sick preterm infants. This finding should prompt clinicians to administer surfactant carefully and cautiously, avoiding vigorous manipulation that may be associated with a significant fluctuation in blood pressure and CBFV and carefully monitoring the drowning effects that may be associated with increase in PACO 2 .
